Other News To Note
Wednesday, August 28, 2013
• Carolus Therapeutics Inc., of San Diego, and The Alpha-1 Project Inc. (TAP), a wholly owned subsidiary of the Alpha-1 Foundation, are collaborating to characterize human biological samples for the presence of the target, RANTES:PF4 heterodimer, a soluble protein complex that is secreted by activated platelets and implicated in many inflammation-related diseases, including genetic emphysema and chronic obstructive pulmonary disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.